Welcome to our dedicated page for Xenetic Biosciences news (Ticker: XBIO), a resource for investors and traders seeking the latest updates and insights on Xenetic Biosciences stock.
Xenetic Biosciences, Inc. (NASDAQ: XBIO) is a biopharmaceutical company that reports a focus on advancing immuno-oncology technologies for difficult to treat cancers. Company news and press releases center on the development of its DNase-based oncology platform, which is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs) involved in cancer progression.
News items for XBIO commonly cover preclinical and translational data from its systemic recombinant human DNase I programs, including the systemic DNase I candidate XBIO-015 in combination with CAR T-cell therapies for hematologic and solid tumors. Updates have described studies conducted with academic collaborators showing that co-administration of DNase I with CAR-T cells can reduce tumor burden, decrease metastatic lesions and extend survival in certain cancer models, while enhancing T-cell infiltration and addressing an immunosuppressive tumor microenvironment.
Another recurring theme in Xenetic’s news flow is collaboration and clinical strategy. The company has announced expanded research and development collaborations with The Scripps Research Institute and a Clinical Trial Services Agreement with PeriNess Ltd. News releases describe exploratory, investigator-initiated clinical studies of systemic DNase I in combination with FOLFIRINOX for unresectable, locally advanced or metastatic pancreatic cancer, and in combination with anti-CD19 CAR T cells in large B cell lymphoma, as well as exploratory plans in osteosarcoma, Ewing sarcoma and colorectal cancer models.
Investors following XBIO news will also find quarterly financial results, details of underwritten offerings conducted under a shelf registration statement, and updates related to annual stockholder meetings and proxy materials. Together, these items provide insight into Xenetic’s progress in advancing its DNase platform toward Phase 1 clinical development, its collaboration-driven development model and its capital-raising activities. Bookmarking this page allows readers to review the sequence of scientific, clinical, financial and corporate announcements directly from the company’s public communications.
Xenetic Biosciences (NASDAQ:XBIO) announced its 2025 Annual Meeting of Stockholders was convened and adjourned on December 11, 2025 due to a lack of quorum.
The meeting will reconvene virtually at 10:00 a.m. ET on Thursday, January 8, 2026. The record date for voting remains October 15, 2025. Stockholders who already voted do not need to re-submit votes; previously submitted proxies remain valid unless revoked.
Stockholders who have not voted are urged to vote by 11:59 p.m. ET on January 7, 2026 via www.proxyvote.com or telephone 1-800-690-6903. Broker-held shares may have earlier deadlines. The reconvened meeting can be attended at http://www.virtualshareholdermeeting.com/XBIO2025.
Xenetic Biosciences (NASDAQ:XBIO) executed a 4-month extension of its R&D collaboration with Scripps Research and Dr. Alexey Stepanov effective November 1, 2025 to advance its systemic DNase I program (XBIO-015) in combination with CAR-T therapies.
Preclinical studies in lymphoma, metastatic melanoma and leukemia models reported that co-administration of DNase I with CAR-T cells reduced tumor burden, decreased metastatic lesions, increased CAR-T and endogenous T-cell tumor infiltration, and extended survival versus CAR-T monotherapy. Xenetic says the program has progressed from proof-of-concept to mechanism-of-action and translational studies in preparation for a Phase 1 clinical trial targeting pancreatic carcinoma and other advanced solid tumors.
Xenetic Biosciences (NASDAQ:XBIO) reported third quarter 2025 results on November 13, 2025, highlighting continued preclinical progress on its systemic DNase I oncology program and partnerships to support investigator‑initiated studies.
Key financials: Q3 net loss ~$0.5M; R&D +105.6% to ~$0.8M; Revenue +67.2% to ~$1.0M driven by Takeda sublicense royalties; quarter‑end cash ~$4.1M and subsequent October 2025 underwritten offering net proceeds of ~$3.9M to extend runway toward IND preparation and Phase 1 initiation.
Xenetic Biosciences (NASDAQ:XBIO) priced an underwritten offering of 735,000 shares of common stock at $6.12 per share for gross proceeds of approximately $4.5 million. The offering is expected to close on or about October 14, 2025, subject to customary closing conditions, with Canaccord Genuity as sole bookrunner.
All shares are being offered by Xenetic and proceeds are intended for working capital and general corporate purposes. The offering is made under a Form S-3 shelf registration declared effective November 1, 2024 (File No. 333-282756); a final prospectus supplement will be filed with the SEC.
Xenetic Biosciences (NASDAQ:XBIO) reported its Q2 2025 financial results, highlighting key developments in its immuno-oncology programs. The company has expanded its strategic partnership with The Scripps Research Institute to advance DNase I combination therapy with CAR T-cells. Through collaboration with PeriNess, Xenetic initiated clinical studies exploring DNase I combinations with anti-CD19 CAR T cells for lymphoma and with FOLFIRINOX for pancreatic cancer.
Financial results showed a net loss of $0.7 million for Q2 2025, with decreased R&D expenses of $0.7 million (down 29.7% YoY) and reduced G&A expenses of $0.7 million (down 41.8% YoY). The company maintained a cash position of $4.8 million at quarter-end.
Xenetic Biosciences (NASDAQ:XBIO) announced that its collaboration partner PeriNess has entered into a Clinical Study Agreement to evaluate DNase I in combination with anti-CD19 CAR T cells for treating large B cell lymphoma. The study will be conducted at Tel Aviv Sourasky Medical Center under Dr. Ron Ram's leadership.
The study aims to assess the safety and efficacy of DNase I as an adjuvant therapy with CAR T treatment. Secondary objectives include measuring complete response rate, duration of response, and overall survival. Preclinical studies have shown that DNase I co-administration with anti-CD19 CAR T cells significantly reduced tumor burden and improved survival compared to CAR T cell monotherapy.
This development follows Xenetic's December 2024 agreement with PeriNess for investigating DNase I as an adjunctive treatment in pancreatic carcinoma and other solid tumors.
Xenetic Biosciences (NASDAQ:XBIO) has expanded its research collaboration with The Scripps Research Institute to advance its DNase platform development. The company's systemic DNase I candidate, XBIO-015, is being developed in combination with CAR-T cell therapy for both hematologic and solid tumors.
Studies have demonstrated that co-administration of DNase I with CAR-T cells significantly reduces tumor burden, decreases metastatic lesions, and extends survival compared to CAR-T cell therapy alone. The research program will now include additional models of lymphoma and leukemia to further validate these findings.
The DNase-based platform targets neutrophil extracellular traps (NETs) in the tumor microenvironment, with preclinical data showing improved efficacy of various cancer treatments. The company is advancing towards Phase 1 clinical development for pancreatic carcinoma and other advanced solid tumors.
Xenetic Biosciences (NASDAQ:XBIO) announced that its collaboration partner PeriNess has begun patient dosing in an exploratory clinical study at Bnei Zion Medical Center in Israel. The study evaluates systemic DNase I in combination with FOLFIRINOX for first-line treatment of unresectable, locally advanced or metastatic pancreatic cancer.
The study, led by Dr. Abed Agbabrya, will assess safety, biomarker response, pharmacokinetics, and clinical activity of DNase I. Patients will receive intravenous DNase I infusions on Days 1 and 8 of 14-day cycles. The trial's effectiveness will be measured through Objective Response Rate (ORR) and Progression-Free Survival (PFS).
This initiative stems from a December 2024 Clinical Trial Services Agreement between Xenetic and PeriNess for exploring DNase as an adjunctive treatment in pancreatic carcinoma and other solid tumors.
Xenetic Biosciences (NASDAQ:XBIO) has released a Virtual Investor segment featuring Dr. Reid Bissonnette, Executive Consultant for Translational Research and Development. The segment focuses on the company's recent poster presentation at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy Meeting.
The presentation, titled 'DNase I Intervention Enhances CAR-T Cell Therapy in Solid Tumors by Targeting Neutrophil Extracellular Traps in Metastatic Melanoma', highlights preclinical data in the company's immune-oncology program targeting difficult to treat cancers.